Hospira Files a Petition for an IPR of Genentech’s Trastuzumab Patent

PTAB + IPR

On September 16, Hospira filed a petition for an inter partes review of Genentech’s U.S. Patent No. 7,807,799 which is directed to methods of purifying proteins, including trastuzumab.  Trastuzumab is marketed by Genentech under the brand-name Herceptin®, and is indicated for the treatment of certain sub-types of breast cancer.

The petition in IPR2016-01837 and other important documents for IPRs filed on biologic patents are posted on our IPR tracker page.

 

Download PDF

Tagged with 

Comments are closed.